Clinical outcomes at 1 year following transcatheter aortic valve replacement

JAMA - Journal of the American Medical Association

Volumn 313, Issue 10, 2015, Pages 1019-1028

  Holmes, David R ^a   Brennan, J Matthew ^b   Rumsfeld, John S ^c   Dai, David ^b   O'Brien, Sean M ^b   Vemulapalli, Sreekanth ^b   Edwards, Fred H ^d   Carroll, John ^e   Shahian, David ^f   Grover, Fred ^e   Tuzcu, E Murat ^g   Peterson, Eric D ^h   Brindis, Ralph G ⁱ   Mack, Michael J ^j  

^a MAYO CLINIC   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AGE; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; DISEASE SEVERITY; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEX DIFFERENCE; TRANSCATHETER AORTIC VALVE IMPLANTATION; UNITED STATES; VERY ELDERLY; ADVERSE EFFECTS; AORTA VALVE; HEART FAILURE; HEART VALVE DISEASES; INCIDENCE; MORTALITY; POSTMARKETING SURVEILLANCE; REGISTER; RISK FACTOR; STATISTICS AND NUMERICAL DATA; STROKE;

AGED; AGED, 80 AND OVER; AORTIC VALVE; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HEART VALVE DISEASES; HUMANS; INCIDENCE; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT READMISSION; PRODUCT SURVEILLANCE, POSTMARKETING; REGISTRIES; RISK FACTORS; STROKE; TRANSCATHETER AORTIC VALVE REPLACEMENT;

EID: 84924350693     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.1474     Document Type: Article

References (34)

1. US Food and Drug Administration. FDA expands approved use of Sapien artificial heart valve [press release]. October 19, 2012. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm323478.htm. Accessed February 17, 2015.
2. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for transcatheter aortic valve replacement (TAVR). http://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDid=355&ncdver=1&NCAid=257&ver=4&NcaName=Transcatheter+Aortic+Valve+Replacement+%28TAVR%29&bc=ACAAAAAACAAAAA%3D%3D&. Accessed November 1, 2013.
3. Carroll JD, Edwards FH, Marinac-Dabic D, et al. The STS-ACC Transcatheter Valve Therapy National Registry: a new partnership and infrastructure for the introduction and surveillance of medical devices and therapies. J AmColl Cardiol. 2013;62 (11):1026-1034.
4. Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med. 2014;371 (10):967-968.
5. Généreux P, Head SJ, Van Mieghem NM, et al. Clinical outcomes after transcatheter aortic valve replacement using valve academic research consortium definitions: a weighted meta-analysis of 3519 patients from 16 studies. J AmColl Cardiol. 2012;59(25):2317-2326.
6. Hamm CW, Möllmann H, Holzhey D, et al; GARY Executive Board. The German Aortic Valve Registry (GARY): in-hospital outcome. Eur Heart J. 2014;35(24):1588-1598.
7. Holmes DR Jr, Mack MJ, Kaul S, et al. 2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement. J AmColl Cardiol. 2012;59(13):1200-1254.
8. Kodali SK, Williams MR, Smith CR, et al; PARTNER Trial Investigators. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med. 2012;366(18):1686-1695.
9. Leon MB, Piazza N, Nikolsky E, et al. Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. J AmColl Cardiol. 2011;57(3):253-269.
10. Leon MB, Smith CR, Mack M, et al; PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363 (17):1597-1607.
11. Smith CR, Leon MB, Mack MJ, et al; PARTNER Trial Investigators. Transcatheter vs surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364(23):2187-2198.
12. Van Mieghem NM, Généreux P, van der Boon RM, et al. Transcatheter aortic valve replacement and vascular complications definitions. EuroIntervention. 2014;9(11):1317-1322.
13. Mack MJ, Brennan JM, Brindis R, et al; STS/ACC TVT Registry. Outcomes following transcatheter aortic valve replacement in the United States. JAMA. 2013;310(19):2069-2077.
14. Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J AmColl Cardiol. 2012;60(15):1438-1454.
15. Dewey TM, Brown D, Ryan WH, HerbertMA, Prince SL, Mack MJ. Reliability of risk algorithms in predicting early and late operative outcomes in high-risk patients undergoing aortic valve replacement. J Thorac Cardiovasc Surg. 2008;135 (1):180-187.
16. Peterson ED, Dai D, DeLong ER, et al; NCDR Registry Participants. Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry. J AmColl Cardiol. 2010;55(18):1923-1932.
17. Gray R. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
18. Gray B. Subdistribution analysis of competing risks. http://CRAN.R-project.org/package=cmprsk. Accessed February 18, 2015.
19. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
20. Kohl M, Heinze G. PSHREG: A SAS Macro for Proportional and Nonproportional Subdistribution Hazards Regression With Competing Risk Data. Vienna, Austria: Medical University of Vienna; 2013.
21. Gilard M, Eltchaninoff H, Iung B, et al; FRANCE 2 Investigators. Registry of transcatheter aortic-valve implantation in high-risk patients. N Engl J Med. 2012;366(18):1705-1715.
22. Moat NE, Ludman P, de Belder MA, et al. Long-term outcomes after transcatheter aortic valve implantation in high-risk patients with severe aortic stenosis: the UK TAVI (United Kingdom Transcatheter Aortic Valve Implantation) Registry. J AmColl Cardiol. 2011;58(20):2130-2138.
23. Nombela-Franco L, Ruel M, Radhakrishnan S, et al. Comparison of hemodynamic performance of self-expandable CoreValve vs balloon-expandable Edwards SAPIEN aortic valves inserted by catheter for aortic stenosis. Am J Cardiol. 2013;111(7):1026-1033.
24. Tamburino C, Capodanno D, Ramondo A, et al. Incidence and predictors of early and late mortality after transcatheter aortic valve implantation in 663 patients with severe aortic stenosis. Circulation. 2011;123(3):299-308.
25. Thomas M, Schymik G,Walther T, et al. Thirty-day results of the SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry: a European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation. 2010;122(1):62-69.
26. Unbehaun A, PasicM, Dreysse S, et al. Transapical aortic valve implantation: incidence and predictors of paravalvular leakage and transvalvular regurgitation in a series of 358 patients. J Am Coll Cardiol. 2012;59(3):211-221.
27. Stähli BE, Tasnady H, Lüscher TF, et al. Early and late mortality in patients undergoing transcatheter aortic valve implantation: comparison of the novel EuroScore II with established risk scores. Cardiology. 2013;126(1):15-23.
28. Iturra SA, Suri RM, Greason KL, et al. Outcomes of surgical aortic valve replacement in moderate risk patients: implications for determination of equipoise in the transcatheter era. J Thorac Cardiovasc Surg. 2014;147(1):127-132.
29. Watanabe Y, Hayashida K, Lefèvre T, et al. Is EuroSCORE II better than EuroSCORE in predicting mortality after transcatheter aortic valve implantation? Catheter Cardiovasc Interv. 2013;81 (6):1053-1060.
30. D'Ascenzo F, Ballocca F, Moretti C, et al. Inaccuracy of available surgical risk scores to predict outcomes after transcatheter aortic valve replacement. J Cardiovasc Med (Hagerstown). 2013;14(12):894-898, 98.
31. Vanhuyse F, Maureira P, Folliguet T, Villemot JP. Predictive value of five risk scores to predict outcomes after aortic valve replacement in octogenarians. J Heart Valve Dis. 2013;22(4):517-523.
32. Chieffo A, Buchanan GL, Van Mieghem NM, et al. Transcatheter aortic valve implantation with the Edwards SAPIEN vs the Medtronic CoreValve revalving system devices: a multicenter collaborative study: the PRAGMATIC Plus Initiative (Pooled-Rotterdam-Milano-Toulouse in Collaboration). J AmColl Cardiol. 2013;61(8):830-836.
33. Mylotte D, Osnabrugge RL,Windecker S, et al. Transcatheter aortic valve replacement in Europe: adoption trends and factors influencing device utilization. J AmColl Cardiol. 2013;62(3):210-219.
34. Rodés-Cabau J,Webb JG, Cheung A, et al. Transcatheter aortic valve implantation for the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive surgical risk: acute and late outcomes of the multicenter Canadian experience. J AmColl Cardiol. 2010;55(11): 1080-1090.